Teva Pharmaceutical Industries Ltd: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

- Benchmark Teva's performance against key rivals in the prescription pharmaceutical sector

- Assess how continued M&A activity has allowed Teva to remain the leading global generics player, despite increased competition from Sandoz

- Analyze how the company is set to experience further uplift from M&A, with the acquisition of Barr due to be completed by early 2009.